Loading...
•
Mar 31, 2024
PMV Pharma Q1 2024 Earnings Report
Reported financial results for the first quarter ended March 31, 2024.
Key Takeaways
PMV Pharma reported first quarter financial results, highlighting the dosing of the first patient in the Phase 2 portion of the PYNNACLE trial and a cash, cash equivalents, and marketable securities balance of $213.1 million as of March 31, 2024.
First patient dosed in Phase 2 portion of the PYNNACLE trial assessing rezatapopt as monotherapy.
Phase 1 data of rezatapopt in advanced ovarian cancer featured at the 2024 SGO Annual Meeting on Women’s Cancer.
Cash, cash equivalents, and marketable securities totaled $213.1 million as of March 31, 2024, providing an expected cash runway to the end of 2026.
Net loss for the quarter ended March 31, 2024, was $15.3 million.
Forward Guidance
The company provided forward-looking statements regarding their future plans and expectations for rezatapopt, including the ability to obtain approval as a treatment option and the timing and success of the Phase 2 portion of the current clinical trial.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...